Arihant Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.45 M
- Paid Up Capital ₹ 0.10 M
- Company Age 45 Year, 26 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.00 M
- Revenue Growth -58.34%
- Profit Growth 137.65%
- Ebitda 98.53%
- Net Worth 15.53%
- Total Assets -66.55%
About Arihant Pharmaceutical
Arihant Pharmaceutical Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 January 1980 and has a history of 45 years. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.45 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.00 M.
Kamlesh Jain and Kumar Preetam serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24230TN1980PTC008067
- Company No.
008067
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jan 1980
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Arihant Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamlesh Jain  | Director | 01-Jul-2010 | Current |
| Kumar Preetam | Director | 29-Sep-1998 | Current |
Financial Performance of Arihant Pharmaceutical.
Arihant Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 58.34% decrease. The company also saw a substantial improvement in profitability, with a 137.65% increase in profit. The company's net worth Soared by an impressive increase of 15.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arihant Pharmaceutical?
In 2018, Arihant Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Alfred Berg Co India P LtdKamlesh Jain is a mutual person
Charges (Loans)
₹4.00 M
₹0
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 0.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jul 2010 | Indian Overseas Bank | ₹4.00 M | Open |
How Many Employees Work at Arihant Pharmaceutical?
Unlock and access historical data on people associated with Arihant Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arihant Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arihant Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
